GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Inventiva Sa IVA · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.84

+1.05%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

16 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 7Strong buy
  • 8Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Average target 15.33

Low
12.00
Average
15.33
Median
13.00
High
24.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$3.8m$12.4m$165.6m$381.8m$722.3m
Revenue, highest$3.8m$12.4m$165.6m$381.8m$722.3m
Revenue, lowest$3.8m$12.4m$165.6m$381.8m$722.3m
Earnings per share-0.69-0.69-0.300.020.66
Earnings per share, highest-0.55-0.42-0.230.020.66
Earnings per share, lowest-0.86-0.92-0.370.020.66
Analysts871155

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q1 2026Q3 2025Q1 2025Q3 2024Q1 2024
Forecast-0.20-0.23-0.41-0.44-0.56-0.40
Reported-0.28-1.07-1.89-2.19-1.01-1.25
Difference-42.0%-365.2%-361.7%-398.1%-81.1%-211.7%

Rating changes

Latest broker notes

  • GuggenheimBuy
  • HC Wainwright & Co.Buy
  • Canaccord GenuityBuy
  • GuggenheimBuy
  • GuggenheimBuy
  • HC Wainwright & Co.Buy
  • HC Wainwright & Co.Buy
  • HC Wainwright & Co.Buy
  • StifelBuy

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

5 / 10

Revenue growth -0.8% a year over 10 years. Return on equity 1241.6%.

Model fair value

4.76

From earnings —, from revenue 4.76.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.